NICE has assessed Spectra Optia to help the NHS decide whether to use this product.
Spectra Optia is an apheresis and cell collection platform which can be used to treat sickle cell disease. It should be considered as an option for automated red blood cell exchange in patients with sickle cell disease who need regular transfusion.
Using Spectra Optia is faster and needs to be done less often than manual red blood cell exchange. NICE has recommended that extra research be done on how using Spectra Optia affects a person’s iron levels over a long time, but there is evidence that automated red blood cell exchange with the device doesn’t add iron in the same way as manual exchange.
This page was last updated: 02 March 2016